Molecular Biology and Immunology of Head and Neck Cancer

Surgical Oncology Clinics of North America

Volumn 24, Issue 3, 2015, Pages 397-407

  Guo, Theresa ^a   Califano, Joseph A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Head and neck cancer; Immunology; Molecular biology; Targeted therapy

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; NIMOTUZUMAB; NIVOLUMAB; NOTCH RECEPTOR; PANITUMUMAB; PEMBROLIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RAS PROTEIN; SORAFENIB; SUNITINIB; TADALAFIL; VANDETANIB; ZALUTUMUMAB;

ADVANCED CANCER; CANCER IMMUNOLOGY; CANCER RADIOTHERAPY; CANCER RISK; CDKN2A GENE; CHEMORADIOTHERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; GENE FUNCTION; GENE IDENTIFICATION; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH RISK POPULATION; HUMAN; MELANOMA; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; ONCOGENE; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; TUMOR SUPPRESSOR GENE; COMPLICATION; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOGENICITY; PROGNOSIS; VIROLOGY;

HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR BIOLOGY; MOLECULAR TARGETED THERAPY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RISK FACTORS;

EID: 84929505977     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2015.03.002     Document Type: Review

References (64)

1. Agrawal N., Frederick M.J., Pickering C.R., et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333(6046):1154-1157.
2. Stransky N., Egloff A.M., Tward A.D., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333(6046):1157-1160.
3. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363(1):24-35.
4. Brennan J.A., Boyle J.O., Koch W.M., et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995, 332(11):712-717.
5. Pulte D., Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010, 15(9):994-1001.
6. D'Souza G., Kreimer A.R., Viscidi R., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007, 356:1944-1956.
7. Scheffner M., Huibregtse J.M., Vierstra R.D., et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75(3):495-505.
8. Pagano M., Durst M., Joswig S., et al. Binding of the human E2F transcription factor to the retinoblastoma protein but not to cyclin A is abolished in HPV-16-immortalized cells. Oncogene 1992, 7(9):1681-1686.
9. Fakhry C., Westra W.H., Li S., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008, 100(4):261-269.
10. The Cancer Genome Atlas Network Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015, 517(7536):576-582.
11. Sun W., Califano J. Sequencing the head and neck cancer genome- Impact on therapy. Ann N Y Acad Sci 2014, 1333:33-42.
12. Lechner M., Frampton G.M., Fenton T., et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med 2013, 5(5):49.
13. Ha P.K., Califano J.A. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 2006, 7(1):77-82.
14. Reed A.L., Califano J., Cairns P., et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996, 56(16):3630-3633.
15. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358(6381):15-16.
16. Califano J., van der Riet P., Westra W., et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996, 56(11):2488-2492.
17. Carr A.M. Cell cycle. Piecing together the p53 puzzle. Science 2000, 287(5459):1765-1766.
18. Haupt Y., Maya R., Kazaz A., et al. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387(6630):296-299.
19. Roussel M.F. The INK4 family of cell cycle inhibitors in cancer. Oncogene 1999, 18(38):5311-5317.
20. Ronchetti D., Neglia C.B., Cesana B.M., et al. Association between p53 gene mutations and tobacco and alcohol exposure in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004, 130(3):303-306.
21. Poeta M.L., Manola J., Goldwasser M.A., et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007, 357(25):2552-2561.
22. Skinner H.D., Sandulache V.C., Ow T.J., et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012, 18(1):290-300.
23. Ganly I., Soutar D.S., Brown R., et al. p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy. Br J Cancer 2000, 82(2):392-398.
24. Perrone F., Bossi P., Cortelazzi B., et al. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol 2010, 28(5):761-766.
25. Ha P.K., Chang S.S., Glazer C.A., et al. Molecular techniques and genetic alterations in head and neck cancer. Oral Oncol 2009, 45(4-5):335-339.
26. Begum S., Gillison M.L., Ansari-Lari M.A., et al. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 2003, 9(17):6469-6475.
27. Li Y., Nichols M.A., Shay J.W., et al. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 1994, 54(23):6078-6082.
28. Weinberg R.A. The biology of cancer 2007, Garland Science, New York.
29. Kalyankrishna S., Grandis J.R. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006, 24(17):2666-2672.
30. Psyrri A., Yu Z., Weinberger P.M., et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005, 11(16):5856-5862.
31. Chung C.H., Ely K., McGavran L., et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006, 24(25):4170-4176.
32. Sun W., Gaykalova D.A., Ochs M.F., et al. Activation of the NOTCH pathway in head and neck cancer. Cancer Res 2014, 74(4):1091-1104.
33. Lui V.W., Hedberg M.L., Li H., et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 2013, 3(7):761-769.
34. Ntziachristos P., Lim J.S., Sage J., et al. From fly wings to targeted cancer therapies: a centennial for notch signaling. Canc cell 2014, 25(3):318-334.
35. Pickering C.R., Zhang J., Yoo S.Y., et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 2013, 3(7):770-781.
36. Weng A.P., Ferrando A.A., Lee W., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306(5694):269-271.
37. Song X., Xia R., Li J., et al. Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma. Clin Cancer Res 2014, 20(3):701-710.
38. Head and neck cancers. NCCN clinical practice guidelines in oncology (NCCN guidelines). 2014. Available at:. Accessed October 24, 2014. http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.
39. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578.
40. Ang K.K., Zhang Q., Rosenthal D.I., et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014, 32:2940-2950.
41. Vermorken J.B., Herbst R.S., Leon X., et al. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008, 112(12):2710-2719.
42. Licitra L., Mesia R., Rivera F., et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 2011, 22(5):1078-1087.
43. Du Y., Peyser N.D., Grandis J.R. Integration of molecular targeted therapy with radiation in head and neck cancer. Pharmacol Therapeut 2014, 142(1):88-98.
44. Vermorken J.B., Stohlmacher-Williams J., Davidenko I., et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013, 14(8):697-710.
45. Huang S.M., Li J., Armstrong E.A., et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002, 62(15):4300-4306.
46. Chinnaiyan P., Huang S., Vallabhaneni G., et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005, 65(8):3328-3335.
47. Caponigro F., Romano C., Milano A., et al. A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. AntiCanc Drugs 2008, 19(7):739-744.
48. Rodriguez C.P., Adelstein D.J., Rybicki L.A., et al. Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck. Head Neck 2012, 34(11):1517-1523.
49. Harrington K., Berrier A., Robinson M., et al. Randomised phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer 2013, 49(7):1609-1618.
50. Hoang T., Huang S., Armstrong E., et al. Enhancement of radiation response with bevacizumab. J Exp Clin Cancer Res 2012, 31:37.
51. Salama J.K., Haraf D.J., Stenson K.M., et al. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol 2011, 22(10):2304-2309.
52. Yoo D.S., Kirkpatrick J.P., Craciunescu O., et al. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res 2012, 18(5):1404-1414.
53. Sano D., Matsumoto F., Valdecanas D.R., et al. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res 2011, 17:1815-1827.
54. Schueneman A.J., Himmelfarb E., Geng L., et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003, 63(14):4009-4016.
55. Yadav A., Kumar B., Teknos T.N., et al. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther 2011, 10(7):1241-1251.
56. Limaye S., Riley S., Zhao S., et al. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral Oncol 2013, 49(8):835-841.
57. Brooks H.D., Glisson B.S., Bekele B.N., et al. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 2011, 117:2112-2119.
58. Sewell A., Brown B., Biktasova A., et al. Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. Clin Cancer Res 2014, 20(9):2300-2311.
59. Bauman J.E., Ferris R.L. Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer 2014, 120(5):624-632.
60. Zandberg D.P., Strome S.E. The role of the PD-L1: PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014, 50(7):627-632.
61. Topalian S.L., Sznol M., McDermott D.F., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, 32(10):1020-1030.
62. Ukpo O.C., Thorstad W.L., Lewis J.S. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol 2013, 7(2):113-121.
63. Serafini P., Meckel K., Kelso M., et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Trace Elem Exp Med 2006, 203(12):2691-2702.
64. Weed D.T., Vella J.L., Reis I., et al. Tadalafil reduces myeloid derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2014, 21:39-48.